206 results about "Polycyclic compound" patented technology

The invention belongs to the technical field of OLEDs, and provides a polycyclic compound containing triphenyl silicon and a polyalkyl substituent group and an organic electroluminescent device containing the polycyclic compound. The structural general formula of the polycyclic compound is as shown in formula I in the specification. Benzofuran with higher electronegativity is introduced to a ring structure composed of nitrogen atoms and boron atoms, triphenyl silicon is introduced to the para-position of boron, and the synergistic effect of benzofuran and triphenyl silicon can significantly enhance the multiple resonance of a light-emitting core and reduce vibration relaxation. Due to simultaneous use of the benzofuran and the triphenyl silicon, the problems of vibration relaxation increase, spectrum widening and the like caused by introduction of the polyalkyl substituent are remarkably improved, the luminous efficiency of the material is remarkably improved, and the color purity is improved, so that the requirement of BT.2020 wide color gamut display standard on a luminescent spectrum is met. I

The present disclosure relates to a polycyclic compound, a preparation method therefor, and the pharmaceutical use thereof. Specifically, the present disclosure relates to a polycyclic compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a therapeutic agent, in particular, the use as an RAS inhibitor and the use in the preparation of a drug for treating and / or preventing RAS-mediated or dependent diseases or conditions, wherein each group in general formula (I) is as defined in the description.

The present invention relates to an organic light-emitting device employing, as a host of a light emission layer, an anthracene derivative compound having a characteristic structure by introduction of a benzofuran structure into the anthracene backbone, and as a dopant of the light emission layer, a polycyclic compound having a characteristic structure. The organic light-emitting device according to the present invention is an organic light-emitting device with significantly improved external quantum efficiency and can be advantageously utilized not only for lighting devices but also for various display devices, such as flat, flexible, and wearable displays.

An organic electroluminescence device includes: a first electrode; a second electrode disposed on the first electrode; and at least one organic layer disposed between the first electrode and the second electrode. wherein the at least one organic layer includes a polycyclic compound having a core structure including a n,n′-bicarbazole moiety and, outside the core structure, at least one optionally substituted carbazole group, and the substituted or unsubstituted carbazole groups of the core structure substituted at any one among carbon atoms at position n±1 of the n,n′-bicarbazole moiety, and any one among carbon atoms at position n′±1 of the n,n′-bicarbazole moiety, respectively; and n and n′ are, independently from one another, integers of 1 to 4 (where n±1 and n′±1 are not 0).

The invention relates to a method for semi-solid-phase synthesis of a polycyclic compound and an intermediate, a long chain is synthesized through solid phase, then two-step ring closing is performed to form a key intermediate, and simple derivation is performed on the basis of the key intermediate to obtain a PCSK9 antagonist compound. According to the invention, starting materials for solid-phase synthesis are selected, steric hindrance is effectively avoided, and solid-phase reaction and subsequent liquid-phase correlation cyclization can be smoothly carried out, so that the yield is improved, and the cost is reduced.

The invention relates to a synthesis method of a polycyclic compound and an intermediate, a long chain is synthesized firstly, then two-step ring closing is performed to form a key intermediate, and simple derivation is performed on the basis of the key intermediate to obtain a PCSK9 antagonist compound. According to the invention, a ring closing route and an intermediate are optimized, and the ring closing yield is improved.

A light emitting device according to an embodiment includes a first electrode and a second electrode facing the first electrode, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one among the plurality of organic layers includes a fused polycyclic compound represented by Formula 1 below, thereby showing improved emission efficiency.

The invention relates to a polycyclic compound, a preparation method thereof and application of the polycyclic compound in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method of the polycyclic compound, a pharmaceutical composition containing the polycyclic compound and application of the polycyclic compound as a therapeutic agent, especially application of the polycyclic compound as a BTK inhibitor or degradation agent and application of the polycyclic compound in preparation of drugs for treating and / or preventing BTK-mediated or dependent diseases or symptoms. Wherein each group in the general formula (I) is defined in the specification.

The invention relates to a light-emitting element, a fused polycyclic compound for the light-emitting element, and an electronic device including the light-emitting element. The light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission layer disposed between the first electrode and the second electrode and including a fused polycyclic compound represented by Formula 1 as a first compound. Formula 1

Disclosed are an organic electroluminescent material and a device thereof. The organic electroluminescent material is a polycyclic compound with a structure of formula 1, which can be used as a TADF material in an organic electroluminescent device. The polycyclic compound has a regulating effect on the emission color, can realize desired green light emission, has deeper HOMO and LUMO energy levels, has the potential to become an excellent light-emitting material, and has a very broad industrial application prospect. Also disclosed are an organic electroluminescent device comprising the compound and a compound composition comprising the compound.

A light emitting element includes a first electrode, a second electrode arranged on the first electrode, and an emission layer arranged between the first electrode and the second electrode and including a first compound represented by Formula 1.

The present invention relates to a pyridine polycyclic compound inhibitor, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the compound, and a use of the compound in a medication for treating chronic kidney disease, kidney or cardiac fibrosis, diabetic nephropathy, congestive heart failure, hypertension, primary aldosteronism, and Cushing syndrome, wherein the definitions of the substituents in formula (I) are the same as those in the description.

The present disclosure relates to dihydropyrimidine-2,4(1H,3H)-dione-containing polycyclic compounds, or pharmaceutically acceptable salts thereof, and compositions thereof which are effective to reduce or modulate widely interspaced zinc finger motifs (WIZ) protein expression levels and / or induce fetal hemoglobin (HbF) expression, and also relates to methods of their preparation and their use in treatment of subjects in need.

The invention relates to a pyrimidine derivative, a preparation method thereof and application of the pyrimidine derivative in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method of the polycyclic compound, a pharmaceutical composition containing the pyrimidine derivative and application of the pharmaceutical composition as a therapeutic agent, especially application of the pharmaceutical composition as a BCL6 inhibitor or a degradation agent and application of the pharmaceutical composition in preparation of drugs for treating and / or preventing BCL6-mediated or dependent diseases or symptoms. Wherein each group in the general formula (I) is defined in the specification.

Provided are a polycyclic compound represented by Formula 1 and an organic light-emitting device and an electronic apparatus, each including the same.

Embodiments provide a fused polycyclic compound, a light emitting element that includes the fused polycyclic compound, and an electronic apparatus that includes the light emitting element. The light emitting element includes a first electrode, a second electrode disposed on the first electrode, and a light emitting layer disposed between the first electrode and the second electrode, wherein the light emitting layer includes the fused polycyclic compound. The fused polycyclic compound is represented by Formula 1, which is explained in the specification.

This application provides a light-emitting device. The light-emitting device includes a first electrode, a second electrode, and an emitting layer disposed between the first and second electrodes. The emitting layer comprises a polycyclic compound represented by Chemical Formula 1. Additionally, an electronic device including the light-emitting device and a polycyclic compound are also provided. Chemical Formula 1.

An organic electroluminescent device of an embodiment is provided. The organic electroluminescent device includes a first electrode and a second electrode disposed opposite to each other, and a plurality of organic layers disposed between the first electrode and the second electrode, wherein at least one among the organic layers includes a fused polycyclic compound represented by the following Formula 1, thereby exhibiting improved emission efficiency. [Formula 1] wherein, X, Y, R 11 to R 21 are the same as defined in the specification.

This application relates to an organic electroluminescent device, comprising: a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region. The emission layer may contain a polycyclic compound represented by Formula 1, thereby exhibiting high luminous efficiency: [Formula 1]

Embodiments provide a fused polycyclic compound, a light-emitting element including the fused polycyclic compound, and an electronic device including the light-emitting element. The light emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission layer disposed between the first electrode and the second electrode, wherein the emission layer includes a fused polycyclic compound. Fused polycyclic compound represented by Formula 1 explained in the description: [Formula 1]

The application belongs to the field of pharmaceutical chemistry, and relates to different hydrochloride salt crystal forms of a polycyclic compound (E)-2-(3-(2-cyano-2-(6-methoxy-3H-imidazo[4,5-c]pyridin-2-yl)vinyl)-2,5-dimethyl-1H-pyrrol-1-yl)-5-methylthiophene-3-carbonitrile, pharmaceutical compositions containing the crystal forms and purposes. The purity, water solubility, chemical stability and crystal form stability of the hydrochloride salt crystal form are all better than those of other crystal forms.

Embodiments provide a light-emitting element that includes a fused polycyclic compound, an electronic device that includes the light-emitting element, and the fused polycyclic compound. The light-emitting element includes a first electrode, a second electrode disposed on the first electrode, and an emission layer disposed between the first electrode and the second electrode, wherein the emission layer includes the fused polycyclic compound. The fused polycyclic compound is represented by Formula 1, which is explained in the specification:

The present application provides a compound of formula (I), or an optical isomer thereof, a pharmaceutically acceptable salt, a solvated form, or a prodrug. The compound may modulate NTCP function for the prevention and / or treatment of HBV / HDV and hepatitis virus-related diseases, bile acid-related cholestasis disorders, metabolic disorders, and / or liver diseases. Additionally, the present application relates to a pharmaceutical composition comprising such a compound and a method for modulating NTCP.

This invention discloses a polycyclic compound and an organic electroluminescent device containing the same. The invention introduces a bridged ring structure to reduce the electron-donating ability of nitrogen atoms, and further weakens this ability through a bridged ring and benzene ring structure, avoiding a redshift in the material's emission. Compared to the benzene ring, the twisted structure of the bridged ring weakens the intermolecular interactions caused by this planar configuration, which is more conducive to the dispersion of dopants in the host material, effectively avoiding fluorescence quenching and improving luminescence efficiency. Simultaneously, the use of a double boron framework allows the material to maintain a narrow half-width at half-maximum (WHM), resulting in devices fabricated using the compound of this invention exhibiting excellent performance in terms of efficiency and lifetime.

The invention relates to a polycyclic compound, a preparation method thereof and application of the polycyclic compound in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method of the polycyclic compound, a pharmaceutical composition containing the polycyclic compound and application of the polycyclic compound as a therapeutic agent, especially application of the polycyclic compound as a BTK inhibitor or degradation agent and application of the polycyclic compound in preparation of drugs for treating and / or preventing BTK-mediated or dependent diseases or symptoms. Wherein each group in the general formula (I) is defined in the specification.

An organic electroluminescence device of an embodiment includes a first electrode, a second electrode facing the first electrode, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one of the plurality of organic layers includes a fused polycyclic compound represented by the following Formula 1, thereby showing improved emission efficiency. Formula 1.

The invention discloses a boron-containing polycyclic compound and an organic photoelectric element containing the same, and belongs to the field of organic photoelectricity. The boron-containing polycyclic compound has a structure as shown in a formula (1) or a formula (2). According to the compound, a boron-containing skeleton and a carbazole derivative are fused through intramolecular conjugation expansion, and a novel rigid unit is constructed. The conjugated fusion not only integrates the electron transport capability of a boron-containing skeleton and the hole transport characteristic and high triplet state energy level of carbazole, but also effectively increases the orbital delocalization range and significantly reduces the singlet state-triplet state energy level difference (delta EST) by reconstructing the distribution of a front line molecular orbital, thereby enhancing the reverse intersystem crossing rate (kRISC) of the compound, and enhancing the efficiency of the compound. And the utilization efficiency of triplet excitons is obviously promoted. When the material is used as a host material to be applied to an organic light-emitting diode, efficient and directional transfer of energy to an object can be ensured, the efficiency of a device is improved, the stability of the device is improved, and the material has a good commercialization prospect.

The invention relates to a polycyclic compound, a preparation method thereof and application of the polycyclic compound in medicine. Specifically, the invention relates to a polycyclic compound as shown in a general formula (I), a preparation method thereof, a pharmaceutical composition containing the compound and application of the compound as a therapeutic agent, in particular to application of the compound in preparation of drugs for inhibiting KRAS amplification and / or mutant activity. Wherein each group in the general formula (I) is defined in the specification.

To provide compounds that find utility as modulators of RapidlyAcceleratedFibrosarcoma (RAF, such as c-RAF, A-RAF and / or B-RAF; target proteins).SOLUTION: The present invention is directed to bifunctional compounds that contain a von Hippel-Lindau, cereblon, Inhibitorsof Apoptosis Proteins, or mousedouble-RAF ligand that binds to the respective E3 ubiquitin ligase at one end and a moiety that binds to the target proteins RAF at the other end, such that the target proteins are placed in proximity to the ubiquitin ligase to effect degradation (and minutehomolog2) of the target proteins. The present disclosure presents a wide range of pharmacological activities related to degradation / inhibition of target proteins.SELECTED DRAWING: None